2 weeks Ago By ABMN Staff
BioLineRx Ltd. ( NASDAQ:BLRX – Get Free Report ) was the target of a large growth in short interest in September. As of September 15th, there was short interest totalling 179,200 shares, a growth of 28.
7% from the August 31st total of 139,200 shares. Based on an average daily trading volume, of 270,600 shares, the short-interest ratio is currently 0.7 days.
Analyst Ratings Changes Separately, StockNews.com upgraded shares of BioLineRx from a “sell” rating to a “hold” rating in a research report on Monday, June 3rd. Check Out Our Latest Analysis on BLRX BioLineRx Trading Down 1.
6 % BioLineRx ( NASDAQ:BLRX – Get Free Report ) last posted its quarterly earnings data on Thursday, August 15th. The biotechnology company reported $0.01 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.
08) by $0.09. The firm had revenue of $5.
39 million for the quarter, compared to the consensus estimate of $3.93 million. On average, equities research analysts anticipate that BioLineRx will post -0.
25 earnings per share for the current fiscal year. Institutional Trading of BioLineRx A hedge fund recently bought a new stake in BioLineRx stock. PVG Asset Management Corp purchased a new position in BioLineRx Ltd.
( NASDAQ:BLRX – Free Report ) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 123,580 shares of the biotechnology company’s stock, valued at approximately $70,000. PVG Asset Management Corp owned 0.
15% of BioLineRx as of its most recent filing with the Securities and Exchange Commission (SEC). Institutional investors own 1.56% of the company’s stock.
About BioLineRx ( Get Free Report ) BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.
Further Reading Receive News & Ratings for BioLineRx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioLineRx and related companies with MarketBeat.com's FREE daily email newsletter ..
